Practical implication
Healthcare professionals must include daraxonrasib in adverse event reporting as the new treatment option is now available for eligible patients.
On August 26, 2026, the FDA approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The drug demonstrated significant improvements in overall and progression-free survival compared to standard chemotherapy regimens in clinical trials.
What changed: Daraxonrasib has been officially approved for use in treating metastatic pancreatic adenocarcinoma, necessitating updates to product labeling and safety communications.
Why it matters: This approval offers a new treatment option for a hard-to-treat cancer, potentially improving outcomes for patients with specific genetic mutations and prior treatment history.
Practical implication: Healthcare professionals must include daraxonrasib in adverse event reporting as the new treatment option is now available for eligible patients.
View original source
- Source: FDA - What's New Drugs RSS
- Published at source: 2026-08-26T00:00:00.000Z
- Discovered by monitor: 2026-08-26T22:31:10.382Z
Published from the regulator source ingestion pipeline after PV impact triage.
